Roquefort Therapeutics (ROQ) Share Price, News & Analysis

Company Overview

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Key Stats

• Today's Range: 2.20 to 2.30
• 50-Day Range: 2.20 to 4.50
• 52-Week Range: 2.15 to 9.50
• Volume: 52,971 shs
• Average Volume: 1.77 million shs
• Market Capitalization: £2.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ROQ Stock Analysis - Frequently Asked Questions

How have ROQ shares performed this year?

Roquefort Therapeutics' stock was trading at GBX 4.10 on January 1st, 2025. Since then, ROQ shares have decreased by 46.2% and is now trading at GBX 2.21.
View the best growth stocks for 2025 here.

How do I buy shares of Roquefort Therapeutics?

Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Roquefort Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:ROQ
• CUSIP: N/A
• CIK: N/A
• Web: www.roquefortinvest.com
• Phone: 44 20 3290 9339
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,519,059.52
• Net Margins: -57,057.07%
• Pretax Margin: N/A
• Return on Equity: -29.57%
• Return on Assets: -15.86%

Debt

• Debt-to-Equity Ratio: 12.37
• Current Ratio: 0.79
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: £2,662.35
• Price / Sales: 1,054.42
• Cash Flow: GBX 1.48 per share
• Price / Cash Flow: 1.49
• Book Value: GBX 3.82 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 127,254,864
• Free Float: N/A
• Market Cap: £2.81 million
• Optionable: Not Optionable
• Beta: 0.05